← All trials
NCT05255276
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 29, 2022
- Primary completion
- May 12, 2022
- Completion date
- Jan 30, 2023
- First posted
- Feb 24, 2022
- Last posted
- Nov 21, 2022
- Enrollment
- 36
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Mirati Therapeutics Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.